Docket No. 3927-4133US2

DEC - 7 mon w

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

HEARING, P., et al.

Group Art Unit:

1633

RECEIVED

Serial No.:

09/530,935

Examiner:

C. Drabik

JAN 0 7 2002

Filed:

September 29, 2000

TECH CENTER 1600/2900

For:

SELECTIVE REGULATION OF ADENOVIRUS PRODUCTION

**EXPRESS MAIL CERTIFICATE** 

Express Mail Label No.:

EF098981588US

Date of Deposit:

December 27, 2001

I hereby certify that the following attached paper(s) and/or fee

- 1. Information Disclosure Statement (3 pages & 1 duplicate page = 4 total pages).
- 2. Form PTO-1449 (2 pages)
- 3. A check in the amount of \$240.00
- 4. Copies of references cited in Form PTO-1449 (21 references)
- 5. Return Receipt Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, Washington, DC 20231

William W. Kim

(Typed or printed name of person mailing papers(s) and/or fee)

December 27, 2001

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.

345 Park Avenue

New York, NY 10154-0053

(212) 758-4800 Telephone

(212) 751-6849 Facsimile

-2-02

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): HEARING, P. et al.

Group Art Unit:

1633

Serial No.:

09/530.935

Examiner:

C. Drabik

JAN 0 7 7 6 7

Filed:

September 29, 2000

TECH UDIVIEW 1600-2900

For:

SELECTIVE REGULATION OF ADENOVIRUS PRODUCTION

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Sir:

and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed: 2. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application. 3. Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_\_\_, filed 4. No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with: 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or 00000086 09530935 01/04/2002 HNOOR1 Repln. Ref: 01/04/2002 HNDDR1 0 DA#:134500 Name/Number:09530935 0011014100 180.00 OP \$60.00 CR

01 FC:126

			37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
			37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
			37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.	
6.	$\boxtimes$	it is be paragr	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(c), after the period specified in raph 4 above but before the mailing date of a final action or a notice of the unce (where there has been no prior final action):
		$\boxtimes$	A check in the amount of \$240.00 is enclosed in payment of the fee.
			Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7.		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:	
			ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and
			e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 elow.
8.		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:	
		a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
		b	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).

	c. The fees due under 37 C.F.R. §§1.17(h) and 1.17(p) are paid as set forth in paragraph 11 below.
9.	I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10.	This document is accompanied by  a Search Report Communication which was cited in a corresponding PCT or Foreign counterpart application
11.	A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).
	Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. <u>13-4500</u> , Order No. <u>3927-4133US2</u> . A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
Dated: <u>D</u>	Respectfully submitted, MQRGAN & FINNEGAN, L.L.P.  By:  Dorothy R. Auth Registration No. 36,434
Correspo	ndence Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone (212) 751-6849 Facsimile